Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators. Nunn AJ, et al. Among authors: torrea g. N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13. N Engl J Med. 2019. PMID: 30865791 Free article. Clinical Trial.
Rifampin drug resistance tests for tuberculosis: challenging the gold standard.
Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC. Van Deun A, et al. Among authors: torrea g. J Clin Microbiol. 2013 Aug;51(8):2633-40. doi: 10.1128/JCM.00553-13. Epub 2013 Jun 12. J Clin Microbiol. 2013. PMID: 23761144 Free PMC article.
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda.
Ngabonziza JS, Habimana YM, Decroo T, Migambi P, Dushime A, Mazarati JB, Rigouts L, Affolabi D, Ivan E, Meehan CJ, Van Deun A, Fissette K, Habiyambere I, Nyaruhirira AU, Turate I, Semahore JM, Ndjeka N, Muvunyi CM, Condo JU, Gasana M, Hasker E, Torrea G, de Jong BC. Ngabonziza JS, et al. Among authors: torrea g. Int J Tuberc Lung Dis. 2020 Mar 1;24(3):329-339. doi: 10.5588/ijtld.19.0298. Int J Tuberc Lung Dis. 2020. PMID: 32228764
Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial.
Ejo M, Van Deun A, Nunn A, Meredith S, Ahmed S, Dalai D, Tumenbayar O, Tsogt B, Dat PT, Ha DTM, Hang PT, Kokebu D, Teferi M, Mebrahtu T, Ngubane N, Moodliar R, Duckworth L, Conradie F, Enduwamahoro E, Keysers J, De Rijk P, Mulders W, Diro E, Rigouts L, de Jong BC, Torrea G. Ejo M, et al. Among authors: torrea g. Int J Tuberc Lung Dis. 2021 Oct 1;25(10):839-845. doi: 10.5588/ijtld.21.0212. Int J Tuberc Lung Dis. 2021. PMID: 34615581 Free PMC article.
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings.
Van Deun A, Bola V, Lebeke R, Kaswa M, Hossain MA, Gumusboga M, Torrea G, De Jong BC, Rigouts L, Decroo T. Van Deun A, et al. Among authors: torrea g. JAC Antimicrob Resist. 2022 Apr 9;4(2):dlac037. doi: 10.1093/jacamr/dlac037. eCollection 2022 Apr. JAC Antimicrob Resist. 2022. PMID: 35415609 Free PMC article.
49 results